Abstract: The present invention provides a respiratory syncytial virus (RSV) recombinant fusion protein (F protein) in which a polymerization domain derived from a foreign protein is bound to the C terminal of a fusion protein (F protein) lacking a transmembrane domain of a wild-type respiratory syncytial virus (RSV) fusion protein (F protein). The recombinant fusion protein of the present invention is soluble and can retain an F protein trimer. Excellent immune-inducing effects can be expected from the recombinant fusion protein of the present invention, and vaccine composition containing same.

Abstract: The present invention provides a gene recombinant respiratory syncytial virus (RSV) in which genes encoding the envelope proteins of an RSV are rearranged, wherein in the RSV, a gene encoding the fusion protein (F protein) derived from a heterologous virus belonging to the family Paramyxoviridae or the family Pneumoviridae is inserted between the genes respectively encoding the glycoprotein (G protein) and the F protein of the RSV, or the gene encoding the F protein of the RSV is substituted with a gene encoding the F protein of a heterologous virus belonging to the family Paramyxoviridae or the family Pneumoviridae. The recombinant RSV of the present invention can be used as an RSV vaccine strain, and can be used as a vaccine due to having excellent stability and safety.

Abstract: Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.

Abstract: Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.